Literature DB >> 23897287

Viral hepatitis: Cell-culture-derived HCV--a promising vaccine antigen.

Judith M Gottwein1, Jens Bukh.   

Abstract

With millions of humans infected yearly with HCV, leading to cirrhosis and cancer, a vaccine is urgently needed. Cultured virus particles constitute the antigen in most antiviral vaccines. A study in mice demonstrated induction of neutralizing antibodies by immunization with cell-culture-derived HCV, providing new possibilities for vaccine development.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23897287     DOI： 10.1038/nrgastro.2013.136

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

Review 1.  Animal models for the study of hepatitis C virus infection and related liver disease.

Authors:  Jens Bukh
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

Review 3.  Hepatitis C virus vaccines--progress and perspectives.

Authors:  Catherine Fauvelle; Quentin Lepiller; Daniel J Felmlee; Isabel Fofana; François Habersetzer; Françoise Stoll-Keller; Thomas F Baumert; Samira Fafi-Kremer
Journal:  Microb Pathog       Date:  2013-03-07       Impact factor: 3.738

4.  Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.

Authors:  Thomas Vanwolleghem; Jens Bukh; Philip Meuleman; Isabelle Desombere; Jean-Christophe Meunier; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

5.  Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Authors:  Judith M Gottwein; Troels K H Scheel; Tanja B Jensen; Jacob B Lademann; Jannick C Prentoe; Maria L Knudsen; Anne M Hoegh; Jens Bukh
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

6.  Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.

Authors:  Daisuke Akazawa; Masaki Moriyama; Hiroshi Yokokawa; Noriaki Omi; Noriyuki Watanabe; Tomoko Date; Kenichi Morikawa; Hideki Aizaki; Koji Ishii; Takanobu Kato; Hidenori Mochizuki; Noriko Nakamura; Takaji Wakita
Journal:  Gastroenterology       Date:  2013-05-11       Impact factor: 22.682

7.  Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies.

Authors:  Jannie Pedersen; Thomas H R Carlsen; Jannick Prentoe; Santseharay Ramirez; Tanja B Jensen; Xavier Forns; Harvey Alter; Steven K H Foung; Mansun Law; Judith Gottwein; Nina Weis; Jens Bukh
Journal:  Hepatology       Date:  2013-08-07       Impact factor: 17.425

Review 8.  Virus-neutralizing antibodies to hepatitis C virus.

Authors:  A Wahid; J Dubuisson
Journal:  J Viral Hepat       Date:  2013-04-04       Impact factor: 3.728

Review 9.  The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.

Authors:  Ralf Bartenschlager; Volker Lohmann; Francois Penin
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

Review 10.  Ever closer to a prophylactic vaccine for HCV.

Authors:  Leo Swadling; Paul Klenerman; Eleanor Barnes
Journal:  Expert Opin Biol Ther       Date:  2013-05-07       Impact factor: 4.388
  10 in total
  7 in total

1.  Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

Authors:  Christian K Mathiesen; Tanja B Jensen; Jannick Prentoe; Henrik Krarup; Alfredo Nicosia; Mansun Law; Jens Bukh; Judith M Gottwein
Journal:  Virology       Date:  2014-05-24       Impact factor: 3.616

Review 2.  Status of hepatitis C virus vaccination: Recent update.

Authors:  Kouka Saadeldin Abdelwahab; Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 3.  Hepatitis C Virus Infection and Vaccine Development.

Authors:  Xuan Guo; Jin-Yi Zhong; Jun-Wen Li
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

4.  High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals.

Authors:  Anne F Pihl; Anna F Offersgaard; Christian K Mathiesen; Jannick Prentoe; Ulrik Fahnøe; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Sci Rep       Date:  2018-11-30       Impact factor: 4.379

Review 5.  [Development approaches for vaccines against hepatitis C virus infections].

Authors:  Dorothea Bankwitz; Thomas Krey; Thomas Pietschmann
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-11       Impact factor: 1.513

6.  HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.

Authors:  Jannick Prentoe; Lieven Verhoye; Rodrigo Velázquez Moctezuma; Caroline Buysschaert; Ali Farhoudi; Richard Wang; Harvey Alter; Philip Meuleman; Jens Bukh
Journal:  Gut       Date:  2015-11-20       Impact factor: 23.059

7.  Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.

Authors:  Keven Lothert; Anna F Offersgaard; Anne F Pihl; Christian K Mathiesen; Tanja B Jensen; Garazi Peña Alzua; Ulrik Fahnøe; Jens Bukh; Judith M Gottwein; Michael W Wolff
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.